Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LYRA: Dara-CyBorD in Multiple Myeloma
NCT02951819Phase 2Completed
- Sponsor
- Janssen Scientific Affairs
- Start
- Nov 2016
- Primary completion
- Mar 2018
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab in multiple myeloma (MM), sponsored by Janssen Scientific Affairs. Primary endpoint: Percentage of Participants Who Achieved Complete Response (CR) or Very Good Partial Response (VGPR) at 4 months. Started Nov 2016; status: completed.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02951819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02951819.